DEA Delays Production Of Marijuana Drug As Potential Treatment For Multiple Sclerosis And Huntington's Disease

MMJ International Holdings, in collaboration with a specialty pharmaceutical solutions company, has been manufacturing gelatin capsule medicines based on compounds found in cannabis. The company will investigate these in clinical trials as potential treatments for multiple sclerosis (MS) and Huntington's disease (HD).

The Providens, Rhode Island-based medical cannabis reserach company had entered into a supply agreement with MMJ BioPharma Cultivation for them to supply strain specific marijuana plants for further processing to potentially obtain FDA approval for its drug.

Problems With The DEA

MMJ BioPharma Cultivation has applied for a DEA bulk manufacturing registration in 2018. The DEA application process is being delayed for years for reasons unknown. The DEA delay has negatively impacted the progression of the drug development for patients suffering from MS and HD.

"As MMJ International Holdings continues to advance to its clinical trials, these DEA delays are unprecedented," stated Elio Mariani, PhD, MMJ's executive responsible for research and development. "The statutory mandate of the DEA is security and divergence and to facilitate the manufacturing of pharmaceuticals to help patients suffering from chronic disease."

Duane Boise, CEO of MMJ International Holdings commented, "MMJ's clinical trials will provide patient dosing, safety, and efficacy data to the FDA to prove that cannabis can treat essential tremors, a neurological disorder that causes involuntary shaking. We firmly believe that our MMJ oral gel cap medication, containing the marijuana plant's unique pharmacological properties, will be FDA-approved as a safe and effective drug."

MMJ International Holdings in 2019 was given DEA clearance to import cannabis-based products into the U.S. from Canada, a process that required the cooperation of multiple governmental agencies, including the FDA and the U.S. Drug Enforcement Agency (DEA) and Health Canada.

To date five approved entities are currently listed on the DEA website but none are manufacturing a pharmaceutical such as MMJ International Holdings with filings with the FDA to perform clinical trials.

 

Posted In: Duane BoiseElio MarianiMMJ BioPharma CultivationMMJ International HoldingsCannabisNewsMarkets

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.